PROJECT AEROVIA-CF1 PATHOGENESIS ATLAS — CYSTIC FIBROSIS

PROJECT AEROVIA-CF1

Atlas Code: SCF-AMC-CF-AEROVIA-PA-0001

Program Phase: Phase 2 — Advanced Pathogenesis Program

Disease Focus: Cystic Fibrosis

Atlas Objective: Reconstruct the complete disease-evolution architecture from CFTR dysfunction to multi-organ progression, with emphasis on pulmonary decline, protease amplification, biofilm adaptation, ECM failure, and systemic disease expansion.

I. PATHOGENESIS CORE MODEL

CFTR Mutation
      ↓
Ion Transport Dysfunction
      ↓
Airway Surface Liquid Depletion
      ↓
Mucus Dehydration + Mucociliary Failure
      ↓
Microbial Persistence
      ↓
Neutrophilic Inflammation
      ↓
Protease Amplification
      ↓
ECM Destabilization
      ↓
Bronchiectasis + Structural Remodeling
      ↓
Progressive Pulmonary Dysfunction
      ↓
Multi-System Disease Burden

II. PRIMARY PATHOGENESIS AXES

Axis	Core Pathogenic Event	Disease Consequence
Genetic Axis	CFTR pathogenic variants	Initiates epithelial dysfunction
Epithelial Axis	Defective chloride/bicarbonate transport	Mucus dehydration and barrier stress
Immune Axis	Chronic neutrophilic activation	Persistent inflammation
Microbial Axis	Biofilm adaptation	Chronic infection persistence
Protease Axis	Neutrophil elastase/MMP activation	Tissue destruction
ECM Axis	Elastin/collagen degradation	Bronchiectasis and remodeling
Metabolic Axis	Oxidative stress and mitochondrial strain	Repair failure and cellular exhaustion
DBI Axis	Communication-network failure	Loss of coordinated repair and defense
CMF Axis	Defense-over-repair prioritization	Maladaptive persistence

III. ORGAN-SPECIFIC PATHOGENESIS MAP

1. Pulmonary Pathogenesis

Stage	Pathogenic Mechanism	Outcome
Early	CFTR dysfunction in airway epithelia	Airway surface liquid imbalance
Establishment	Thickened mucus and impaired clearance	Microbial persistence
Amplification	IL-8/CXCL signaling and neutrophil recruitment	Chronic inflammation
Injury	Elastase, MMP-9, cathepsin G, proteinase-3	ECM degradation
Structural	Airway dilation and remodeling	Bronchiectasis
Advanced	Gas exchange impairment	Respiratory insufficiency

2. Pancreatic Pathogenesis

Stage	Mechanism	Outcome
Early	Ductal obstruction	Exocrine dysfunction
Progressive	Enzyme flow impairment	Malabsorption
Advanced	Tissue injury and fibrosis	Pancreatic insufficiency
Endocrine	Islet stress	CF-related diabetes risk

3. Gastrointestinal Pathogenesis

Stage	Mechanism	Outcome
Neonatal	Thick intestinal secretions	Meconium ileus risk
Chronic	Altered mucus and motility	Dysbiosis, obstruction risk
Nutritional	Malabsorption	Growth and metabolic burden

4. Hepatobiliary Pathogenesis

Stage	Mechanism	Outcome
Early	Altered bile viscosity	Cholestatic stress
Progressive	Ductal injury and inflammation	Fibrosis risk
Advanced	Portal and hepatic complications	Liver disease subset

IV. MULTI-OMICS PATHOGENESIS LAYERS

Omics Layer	Pathogenic Signal	SCF Interpretation
Genomics	CFTR variants; modifier genes	Origin and severity architecture
Epigenomics	Inflammatory memory; stress adaptation	Disease persistence programming
Transcriptomics	IL-8, TNF, NF-κB, CXCL pathways	Inflammatory amplification
Proteomics	Neutrophil elastase, MMP-9, cathepsin G	Structural injury engine
Metabolomics	ROS, glutathione depletion, mitochondrial stress	Repair-energy imbalance
Microbiomics	Pseudomonas, Staphylococcus, polymicrobial biofilms	Ecological persistence
Interactomics	Epithelial–immune–microbial cross-talk	Communication instability
Biomechanicalomics	Airway stiffness, ECM tension, dilation	Structural failure progression

V. SCF FAULT-TO-PATHOGENESIS MAP

Fault Tier	Pathogenesis Role	Clinical Consequence
Genomic Fault	CFTR mutation	Disease susceptibility
Molecular Fault	Ion transport failure	Dehydrated secretions
Cellular Fault	Epithelial stress	Adaptive reprogramming
Tissue Fault	Mucosal instability	Obstruction
Immune Fault	Neutrophil dominance	Chronic inflammation
Ecological Fault	Biofilm persistence	Recurrent infection
Protease Fault	Elastase amplification	ECM degradation
Structural Fault	Airway remodeling	Bronchiectasis
Organ Fault	Pulmonary/pancreatic decline	Multisystem disease
System Fault	DBI communication collapse	Heterogeneous progression

VI. PATHOGENESIS PROGRESSION CASCADE

Phase A — Initiation

CFTR dysfunction disrupts epithelial ion and fluid regulation.

Phase B — Establishment

Mucus dehydration creates impaired clearance and epithelial stress.

Phase C — Amplification

Immune recruitment and microbial persistence form a chronic inflammatory loop.

Phase D — Protease Dominance

Neutrophil elastase and related proteases convert defense into tissue injury.

Phase E — Structural Destabilization

ECM breakdown weakens airway architecture.

Phase F — Remodeling

Bronchiectatic remodeling becomes self-reinforcing.

Phase G — Systemic Expansion

Nutritional, metabolic, hepatobiliary, endocrine, and immune burden accumulate.

VII. CMF PATHOGENESIS INTERPRETATION

CMF Decision State	Pathogenic Effect
Survival preservation	Maintains viability despite dysfunction
Barrier preservation	Increases secretory/mucosal adaptation
Defense prioritization	Sustains neutrophilic inflammation
Resource reallocation	Diverts energy away from repair
Repair suppression	Allows ECM injury accumulation
Adaptive lock-in	Stabilizes chronic disease state
Maladaptive persistence	Drives progression and structural collapse

VIII. DBI PATHOGENESIS INTERPRETATION

DBI Network	Pathogenic Disruption
Epithelial intelligence	Loss of coordinated fluid and barrier regulation
Immune intelligence	Persistent threat overestimation
Microbial intelligence	Biofilm adaptation and ecological stabilization
Structural intelligence	ECM repair coordination failure
Metabolic intelligence	Energy allocation toward defense over regeneration
Whole-system intelligence	Multi-organ disease coordination failure

IX. PATHOGENESIS BIOMARKER MAP

Pathogenic Domain	Candidate Biomarkers
CFTR dysfunction	Sweat chloride, CFTR functional assays
Inflammation	IL-8, TNF-α, CRP
Neutrophilic injury	Neutrophil elastase
ECM degradation	Elastin fragments, MMP-9
Oxidative stress	Glutathione status, ROS markers
Infection ecology	Sputum microbiome, pathogen burden
Structural progression	CT bronchiectasis scoring, FEV1, LCI
Systemic burden	Nutritional markers, glucose tolerance, liver markers

X. STRATEGIC PATHOGENESIS VULNERABILITIES

Priority Vulnerability 1 — Protease Amplification

Target: neutrophil elastase/MMP injury loop.

Opportunity: structural preservation and progression slowing.

Priority Vulnerability 2 — Biofilm–Inflammation Coupling

Target: chronic microbial persistence and immune amplification.

Opportunity: reduce recurrent exacerbation biology.

Priority Vulnerability 3 — ECM Destabilization

Target: elastin/collagen injury and repair failure.

Opportunity: bronchiectasis prevention.

Priority Vulnerability 4 — Epithelial Adaptive Lock-In

Target: early epithelial reprogramming.

Opportunity: disease interception before irreversible injury.

Priority Vulnerability 5 — DBI Communication Failure

Target: epithelial–immune–microbial–structural signaling collapse.

Opportunity: restore coordinated disease control.

XI. PATHOGENESIS ATLAS CONCLUSION

Cystic fibrosis pathogenesis is best modeled as a progressive, multi-system cascade initiated by CFTR dysfunction but sustained by inflammation, microbial adaptation, protease amplification, ECM degradation, and communication-network failure.

The highest-value pathogenesis targets for PROJECT AEROVIA-CF1 are:

Protease amplification.
ECM destabilization.
Chronic inflammatory adaptation.
Biofilm persistence.
Early epithelial adaptive lock-in.
DBI communication failure.

MANDATORY DELIVERABLE STATUS

Deliverable	Status
Pathogenesis Atlas	Complete
Organ-Specific Pathogenesis Map	Complete
Multi-Omics Pathogenesis Layer	Complete
Fault-to-Pathogenesis Map	Complete
CMF/DBI Pathogenesis Interpretation	Complete
Strategic Vulnerability Identification	Complete